Aerie Pharmaceuticals receives positive CHMP opinion for Rhokiinsa® in the European Union
Aerie Pharma announced the EMA's CHMP has adopted a positive opinion recommending approval of the MAA for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. The recommended indication is reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma. September 20, 2019